| Rebecca Shoemaker, | |
|
6985 Coal Creek Pkwy Se, Newcastle, WA 98059-3136 | |
| (425) 378-0500 | |
| (425) 378-8168 |
| Full Name | Rebecca Shoemaker |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 5 Years |
| Location | 6985 Coal Creek Pkwy Se, Newcastle, Washington |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396378204 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 61029436 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Movement Systems Physical Therapy, P.s. | 3577524974 | 11 |
News Archive
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
A new report, titled "Injection Drug Use in Ukraine" and published by the Center for Strategic & International Studies (CSIS), examines the challenges of providing HIV prevention and care services in the country, particularly to people who inject drugs (PWID), who accounted for "nearly 50 percent of new HIV infections registered in 2010," according to the CSIS website.
Intestinal worm infections can leave women in sub-Saharan Africa more vulnerable to sexually-transmitted viral infections, a new study reveals.
Yale School of Medicine researchers have shown for the first time that it is possible to suppress the development of epilepsy in genetically predisposed animals - which could open the door to treating epilepsy as a preventable disease.
› Verified 9 days ago
| Entity Name | Apple Physical Therapy Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902808470 PECOS PAC ID: 7810892072 Enrollment ID: O20031202000184 |
News Archive
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
A new report, titled "Injection Drug Use in Ukraine" and published by the Center for Strategic & International Studies (CSIS), examines the challenges of providing HIV prevention and care services in the country, particularly to people who inject drugs (PWID), who accounted for "nearly 50 percent of new HIV infections registered in 2010," according to the CSIS website.
Intestinal worm infections can leave women in sub-Saharan Africa more vulnerable to sexually-transmitted viral infections, a new study reveals.
Yale School of Medicine researchers have shown for the first time that it is possible to suppress the development of epilepsy in genetically predisposed animals - which could open the door to treating epilepsy as a preventable disease.
› Verified 9 days ago
| Entity Name | Movement Systems Physical Therapy, P.s. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659324051 PECOS PAC ID: 3577524974 Enrollment ID: O20041019001440 |
News Archive
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
A new report, titled "Injection Drug Use in Ukraine" and published by the Center for Strategic & International Studies (CSIS), examines the challenges of providing HIV prevention and care services in the country, particularly to people who inject drugs (PWID), who accounted for "nearly 50 percent of new HIV infections registered in 2010," according to the CSIS website.
Intestinal worm infections can leave women in sub-Saharan Africa more vulnerable to sexually-transmitted viral infections, a new study reveals.
Yale School of Medicine researchers have shown for the first time that it is possible to suppress the development of epilepsy in genetically predisposed animals - which could open the door to treating epilepsy as a preventable disease.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rebecca Shoemaker, 810 12th Ave Apt 326, Seattle, WA 98122-4433 Ph: (703) 944-4195 | Rebecca Shoemaker, 6985 Coal Creek Pkwy Se, Newcastle, WA 98059-3136 Ph: (425) 378-0500 |
News Archive
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
A new report, titled "Injection Drug Use in Ukraine" and published by the Center for Strategic & International Studies (CSIS), examines the challenges of providing HIV prevention and care services in the country, particularly to people who inject drugs (PWID), who accounted for "nearly 50 percent of new HIV infections registered in 2010," according to the CSIS website.
Intestinal worm infections can leave women in sub-Saharan Africa more vulnerable to sexually-transmitted viral infections, a new study reveals.
Yale School of Medicine researchers have shown for the first time that it is possible to suppress the development of epilepsy in genetically predisposed animals - which could open the door to treating epilepsy as a preventable disease.
› Verified 9 days ago